Drug General Information (ID: DDIC0FWI29)
Drug Name			Glimepiride		Drug Info		Dulaglutide		Drug Info
Drug Type		Small molecule				Protein/peptide
Therapeutic Class		Antidiabetic Agents				Antidiabetic Agents

Mechanism of Glimepiride-Dulaglutide Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Glimepiride				Dulaglutide
Mechanism		Hypoglycemic effects				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Glimepiride and Dulaglutide

Recommended Action
Management		A lower dosage of the insulin secretagogue may be required when used in combination with a GLP-1 receptor agonist. Blood glucose should be monitored closely, and patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.

References
1	Product Information. Adlyxin (lixisenatide). sanofi-aventis, Bridgewater, NJ.
2	Product Information. Trulicity (dulaglutide). Eli Lilly and Company, Indianapolis, IN.
3	Product Information. Ozempic (semaglutide). Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.